Gustave Roussy
Villejuif, 94800, France
Location status: Recruiting
NCT Number: NCT06479057
PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care.
This is an observational cohort study in the context of a quality-of-care initiative.
It will be evaluated by its impact on patient's distress measured by the NCCN's Distress thermometer at 12 weeks after entering the pathway.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Villejuif, 94800, France
Location status: Recruiting
The primary study endpoint of PROACT is patient distress and supportive care needs (NCCN Distress Thermometer and NCCN Problem list) over a 12-week period after the supportive care needs assessment and referrals in the context of a PROACT pathway.
Secondary study endpoints include:
This is a master protocol study that is conducted by collecting sub-studies for each supportive care intervention which share key design components and operational aspects leading to a higher level of coordination than the one achieved by independently conducted studies.
Methodology: it is a mix of quantitative and qualitative methods to assess the Reach, Efficacy and potential for Adoption, while identifying barriers to Implementation and strategies to Maintain the pathway in the institution guided by the RE-AIM framework. Data collection will allow evaluation in a macro level (integrated supportive care pathway including supportive care needs assessment and tailored multidisciplinary referrals) and in a micro level (separated for each supportive care intervention).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
Time frame: over a 12-week period after the integrated supportive care needs assessment.
Patient distress collected with NCCN Distress Thermometer
Time frame: over a 12-week period after the integrated supportive care needs assessment.
Patient unmet needs collected with problem list from NCCN Distress thermometer
Time frame: week 12
Proportion of patients who accepted the supportive care needs assessment (descriptive numbers from attendance log)
Time frame: week 12
Socioeconomic characteristics of participants in the pathway measure by a self-reported socioeconomic questionnaire
Time frame: week 12, and 24
Overall health status measured by the EQ-ED-5L
Time frame: week 12, and 24
Quality of life measured by the EORTC QLQ C30
Time frame: week 12, and 24
Symptom burden measured by the MDASI Questionnaire.
Time frame: week 12, and 24
Anxiety measured by HADS
Time frame: week 12, and 24
Insomnia measured by ISI
*only for patients reporting insomnia at baseline
Time frame: week 12, and 24
Sexual health measured by EORTC SHQ-C22
*only for patients reporting sexual dysfunction at baseline
Time frame: week 12
Proportion of physicians referring patients to the supportive care pathway (descriptive numbers from referral logs)
Time frame: week 12
Proportion and of patients that fully adopted each supportive care intervention (e.g.; in the after cancer pathway: attendance to consultations/seminaries/classes, completion of a supportive care program, usage data for Resilience app).
Time frame: week 12
Patient experience measured by the PACIC questionnaire.
Time frame: week 12
Patient satisfaction measured by an ad hoc satisfaction questionnaire
Time frame: week 12
Focus groups with healthcare providers to explore overall experience, workload and implementation challenges
Time frame: week 12
Focus groups with patient to explore overall experience and implementation challenges
Time frame: week 12
Maintenance of the pathway through a cost effectiveness analysis. Costs from the perspective of the French national health insurance will be assessed during the study period. This will be calculated by administrative data review of internal allocated resources for pathway delivery and estimated costs of use of hospital services (unplanned hospitalization, consultations, and emergency visits recorded in the electronic medical records).
QALYs (quality-adjusted life years) will be measured using utility values derived from the EuroQol-5D (EQ-5D-5L) (https://euroqol.org/) for French general population (Andrade et al. PharmacoEconomics 2020). QALYs will be computed combining survival time by utility values.
Time frame: week 24
Intestinal Symptoms measured by LARS score.
*only for patients with digestive cancer
Time frame: week 24
Anal incontinence measured by Wexner score.
*only for patients with digestive cancer
Time frame: week 24
Urinary symptoms measured by USP score.
*only for patients with digestive cancer
Time frame: week 12, week 24
Functional Assessment of Cancer Therapy-Bone Marrow Transplant measured by FACT-BMT score.
*only for patients with Hematologic Cancer
Time frame: week 12
Caregiver burden measured by Montgomery Borgatta Caregiver Burden Scale.
Time frame: week 12
Healthcare professionals measured by F-SUS Score
Contact information is provided by the study sponsor or research team.
Aude BARBIER
CONTACT
Maria Alice BORINELLI-FRANZOI
CONTACT
Gustave Roussy, Cancer Campus, Grand Paris
Other
Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)
Acronym: PROACT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724535
Cancer, Neoplasms
Beijing, Beijing Municipality, China
View Trial DetailsNCT03854318
Disease Attributes, FPDMM
Bethesda, Maryland, United States
View Trial DetailsNCT07117058
Anxiety Disorders, Behavior
Caen, France
View Trial DetailsNCT06744283
Anemia, Anemia, Aplastic
Bethesda, Maryland, United States
View Trial Details